Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Metric	Value
Current Market Cap	$50.78M
Last Price	$7.58
52-Week High	$7.51
52-Week Low	$0.24

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RLMD	$7.58	+8.20%	1.45M
3
4
5

Relmada Therapeutics Inc. (RLMD) Market Capitalization

Market Cap Data

Get Relmada Therapeutics Inc. Data in Excel

More RLMD Financial Data